Glioblastoma Multiforme (GBM) Treatment Market Outlook 2028

  • The global glioblastoma multiforme (GBM) treatment market was valued at US$ US$ 1.61 Bn in 2020
  • It is estimated to expand at a CAGR of 8.1% from 2021 to 2028
  • The global glioblastoma multiforme (GBM) treatment market is expected to reach the value of US$ 3.72 Bn by the end of 2028

Analysts’ Viewpoint Glioblastoma Multiforme (GBM) Treatment Market Scenario

Since active COVID-19 infection cases are declining in most countries except for regions such as Shanghai in China, participants in the glioblastoma multiforme (GBM) treatment market are witnessing an uptick in market growth. However, poor medical outcomes in GBM patients are discouraging patients to seek medical treatment. Hence, market players should offer better reimbursement packages to individuals to encourage GBM patients for seeking medical treatment. Healthcare companies should increase awareness about early diagnosis of GBM through marketing in order to reduce its severity in potential patients. In addition, healthcare companies should invest in R&D by seeking funds from cancer organizations to develop better treatment alternatives in chemo, drugs, and radiotherapy to improve patient outcomes.

Positive Regulatory Framework in U.S. Benefitting Healthcare Companies

Mature healthcare markets such as the U.S. in North America are creating stable revenue streams for market stakeholders. North America is projected to be a highly lucrative region for the glioblastoma multiforme (GBM) treatment market throughout the assessment tenure. Major healthcare companies are bullish on investments in R&D for increasing the availability of treatment options across the region.

Leading-edge and advanced healthcare infrastructure in the U.S. has aided in the development of drug repurposing for the treatment of glioblastoma multiforme. Moreover, favorable regulatory environment is a key factor propelling the glioblastoma multiforme (GBM) treatment market in North America. A positive legal and regulatory environment facilitates the development and early acceptance of GBM medications.

Request a sample to get extensive insights into the Brazil Parenteral Nutrition Market

Relaxation in COVID-19 Restrictions Increasing Footfalls in Healthcare Facilities

Since glioblastoma multiforme is a potentially life-threatening autoimmune disorder, healthcare stakeholders in the glioblastoma multiforme (GBM) treatment market are striving to ensure the availability of radiation therapy and chemotherapy amid the ongoing COVID-19 pandemic. Pharmaceutical companies have been working at breakneck speeds to maintain robust supply for life-altering therapeutics, medications, and other drugs at hospitals, ambulatory surgical centers, and clinics.

Healthcare companies are taking data-driven decisions before investing in R&D for drug development and other therapeutic innovations. They are capitalizing on government stimulus packages in order to keep economies going. Relaxations in pandemic related restrictions are helping to increase footfalls in healthcare facilities.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Funding from Healthcare Organizations Hold Potentials for Better GBM Treatment Outcomes

The global glioblastoma multiforme (GBM) treatment market is increasingly sensitive toward R&D, manufacturing costs, as well as market price, since the market is challenged with high morbidity and mortality rates. For small- or medium-scale healthcare companies, glioblastoma multiforme treatment research & development requires significant amount of resources and capital. Such trends are inhibiting market growth.

Glioblastoma multiforme (GBM) treatment is a commonly found cancer but it is associated with poor medical outcomes, owing to its aggressive nature for metastasis in the human body. These findings are triggering the need for high investment in R&D activities. Hence, uncertainty over expected profit deters companies from entering the market. Thus, companies should work closely with major healthcare organizations to increase funding for R&D.

Stuck in a neck-to-neck competition with other brands? Request a custom report on Traditional Chinese Herbal Medicine for Face-care Market

Surging Demand for Glioblastoma Multiforme Treatment to Propel Global Market

The rise in prevalence of chronic diseases such as cancer, cardiovascular diseases, and diabetes is expected to drive the glioblastoma multiforme (GBM) treatment market. However, it has been found that survival rate of patients suffering from GBM is relatively poor.

Very few patients survive for 2.5 to 5 years following diagnosis. According to the data published by the Centers for Disease Control and Prevention (CDC), a national public health agency of the U.S., 90% of the adult patients with GBM die within 24 months after diagnosis. Moreover, the incidence of GBM ranges from 0.59 to 5 per 100,000 individuals, and this rate is increasing in multiple countries across the globe. The figures above indicate that the demand for treatment is likely to increase exponentially, which, in turn, is projected to augment the global glioblastoma multiforme (GBM) treatment market.

R&D Helps Accelerate Treatment Options for Glioblastoma Multiforme

Companies in the glioblastoma multiforme (GBM) treatment market are expected to join forces with researchers from universities to fast-track the drug development of glioblastoma. Such collaborations are encouraging international cancer organizations to fund R&D activities. Pharmaceutical companies are entering into cooperation agreement with research centers for the clinical development of radiopharmaceutical therapy, for the treatment of glioblastoma multiforme.

Innovative healthcare therapeutics companies are announcing the early results from phase 1 trials of its glioblastoma multiforme treatment alternative. The treatment was developed using peptide inhibitor to fight against recurrent high-grade gliomas.

Glioblastoma Multiforme Treatment (GBM) Market: Overview

  • According to Transparency Market Research’s latest report on the global glioblastoma multiforme treatment (GBM) market for the historical period 2017–2019 and forecast period from 2021 to 2028, increase in research funding, rise in government support, improved regulatory framework, technological advancements, and surge in prevalence of chronic glioblastoma multiforme disease are projected to drive the global glioblastoma multiforme treatment (GBM) market during the forecast period

Increase in Approvals for Glioblastoma Multiforme Treatment: Key Driver

  • Glioblastoma Multiforme (GBM) is the most common and aggressive form of primary brain cancer
  • Increase in approvals for novel and combination therapies is projected to propel the global glioblastoma multiforme treatment (GBM) market during the forecast period
  • In December 2021, Sapience Therapeutics, Inc., a biotech firm specialized in developing novel therapeutics to treat oncology indications, received the U.S. Food and Drug Administration's (FDA) fast track designation for ST101. ST101 is a peptide inhibitor of C/EBPβ for the treatment of patients with glioblastoma multiforme (GBM). In June 2019, the FDA granted Pfizer’s Zirabev, a mAb biosimilar of the reference product, Avastin, for the treatment of glioblastoma, colorectal cancer, and others diseases. In January 2020, the company announced the launch of the product in the U.S.

Surge in Incidence of Glioblastoma Multiforme: Major Driver

  • Rise in awareness about chemotherapy treatment is projected to drive the global glioblastoma multiforme (GBM) treatment market during the forecast period
  • Increase in cases of brain and other nervous system cancers across the world is another factor anticipated to propel the glioblastoma multiforme (GBM) treatment market. Several companies emphasize on inventing generic products for the treatment of glioblastoma to strengthen their presence across the developing & developed countries and maintain their competitive advantage. Moreover, increase in funding and grants for companies engaged in research activities related to glioblastoma are expected to augment the global market during the forecast period.

High Cost of Glioblastoma Multiforme Treatment R&D and Manufacturing to Hamper Market

  • The global glioblastoma multiforme treatment (GBM) market is concerned about R&D and manufacturing costs as well as market price. For a developing organization, glioblastoma multiforme treatment research & development requires significant resources.
  • Glioblastoma multiforme treatment (GBM) is a niche segment and requires high investment. Hence, uncertainty over expected profit deters companies from entering the market.

Glioblastoma Multiforme Treatment (GBM) Market: Competition Landscape

  • This report profiles major players in the global glioblastoma multiforme treatment (GBM) market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global glioblastoma multiforme treatment (GBM) market is quite competitive, with the top 10 players accounting for major share of the market and companies focusing on research & development to produce better pharmaceutical and vaccine products for the existing diseases
  • Leading players operating in the global glioblastoma multiforme treatment (GBM) market are
    • AbbVie Inc.
    • Activartis GmbH
    • Agenus Inc.
    • Arog Pharmaceuticals Inc.
    • Bristol-Myers Squibb Company
    • Cavion LLC
    • Celldex Therapeutics Inc.
    • CTI BioPharma Corporation (formerly Cell Therapeutics Inc.)
    • Cortice Biosciences Inc.
    • Eisai Co. Ltd.
    • Exelixis Inc.
    • F. Hoffmann-La Roche Ltd.
    • Peregrine Pharmaceuticals Inc.
    • OncoSynergy
    • Merrimack Pharmaceuticals Inc.

Glioblastoma Multiforme Treatment (GBM) Market: Key Developments

  • Key players in the global glioblastoma multiforme treatment (GBM) market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to drive the global glioblastoma multiforme treatment (GBM) market.
  • A few expansion strategies adopted by players operating in the global glioblastoma multiforme treatment (GBM) market are:
  • In February 2022, a researcher from the University of Alabama at Birmingham (UAB) Department of Pathology received a US$ 3.09 Mn R01 grant from the National Cancer Institute in order to fast-track the drug development for glioblastoma
  • In January 2022, ITM Isotope Technologies Munich SE, a Germany-based pharmaceutical company, entered into cooperation agreement with Helmholtz Zentrum München, the German Research Center for Environmental Health for the clinical development of radiopharmaceutical therapy, for the treatment of glioblastoma multiforme
  • In November 2021, OX2 Therapeutics, Inc., an innovative healthcare therapeutics company, announced the early results from phase 1 trials of its glioblastoma multiforme treatment (GBM). The treatment was developed using peptide inhibitor to fight against recurrent high-grade gliomas.
  • The report on the global glioblastoma multiforme treatment (GBM) market discusses individual strategies followed by company profiles of manufacturers of glioblastoma multiforme treatment (GBM) devices. The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global glioblastoma multiforme treatment (GBM) market.

Glioblastoma Multiforme Treatment (GBM) Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 1.61 Bn

Market Forecast Value in 20231

US$ 3.72 Bn

Growth Rate (CAGR)

8.1%

Forecast Period

2021–2028

Quantitative Units

US$ Mn for Value

Market Analysis

It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2020)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Treatment
    • Radiation Therapy
    • Chemotherapy
      • Temozolomide
      • Bevacizumab
      • Carmustine
      • Other Types of Chemotherapy
    • Other Treatments
  • End-user
    • Hospitals
    • Ambulatory Surgical Centers
    • Clinics

Regions Covered

  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Merck & Co., Inc.
  • Amgen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Amgen, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Arbor Pharmaceuticals, LLC
  • Amneal Pharmaceuticals
  • Karyopharm Therapeutics, Inc.
  • Other prominent players

Customization Scope

Available upon request

Pricing

Available upon request

Glioblastoma Multiforme Treatment (GBM) Market – Segmentation

Treatment
  • Radiation Therapy
  • Chemotherapy
    • Temozolomide
    • Bevacizumab
    • Carmustine
    • Other Types of Chemotherapy
  • Other Treatments
End-user
  • Hospitals
  • Ambulatory Surgical Centers
  • Clinics
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

Glioblastoma multiforme (GBM) treatment market is expected to reach the value of US$ 3.72 Bn by the end of 2028

Glioblastoma multiforme (GBM) treatment market is estimated to expand at a CAGR of 8.1% from 2021 to 2028

Glioblastoma multiforme (GBM) treatment market is driven by rise in prevalence of chronic diseases such as cancer, cardiovascular diseases, and diabetes

North America accounted for the largest share of the global glioblastoma multiforme (GBM) treatment market

Key players in the global glioblastoma multiforme (GBM) treatment market include Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Pfizer, Inc., Amgen, Inc., Teva Pharmaceutical Industries Ltd.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Glioblastoma Multiforme Treatment (GBM) Market 

4. Market Overview

    4.1. Introduction

        4.1.1. Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast, 2017–2028

5. Key Insights

    5.1. Regulatory Scenario, by Region/globally

    5.2. Key Mergers & Acquisitions 

    5.3. Technological Advancements

    5.4. COVID-19 Pandemics Impact on Industry

6. Global Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast, by Treatment

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Treatment, 2017–2028

        6.3.1. Radiation Therapy

        6.3.2. Chemotherapy

            6.3.2.1. Temozolomide

            6.3.2.2. Bevacizumab

            6.3.2.3. Carmustine

            6.3.2.4. Other Types of Chemotherapy

        6.3.3. Other Treatments

    6.4. Market Attractiveness Analysis, by Treatment

7. Global Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast, by End-user 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by End-user, 2017–2028

        7.3.1. Hospitals

        7.3.2. Ambulatory Surgical Centers

        7.3.3. Clinics

    7.4. Market Attractiveness Analysis, By End-user 

8. Global Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Market Value Forecast, by Region

        8.2.1. North America  

        8.2.2. Europe 

        8.2.3. Asia Pacific 

        8.2.4. Latin America 

        8.2.5. Middle East & Africa 

    8.3. Market Attractiveness Analysis, By Country/Region

9. North America Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast, by Treatment, 2017–2028

        9.2.1. Radiation Therapy

        9.2.2. Chemotherapy

            9.2.2.1. Temozolomide

            9.2.2.2. Bevacizumab

            9.2.2.3. Carmustine

            9.2.2.4. Other Types of Chemotherapy

    9.3. Market Value Forecast, by End-user, 2017–2028

        9.3.1. Hospitals

        9.3.2. Ambulatory Surgical Centers

        9.3.3. Clinics

    9.4. Market Value Forecast, by Country, 2017–2028

        9.4.1. U.S. 

        9.4.2. Canada 

    9.5. Market Attractiveness Analysis 

        9.5.1. By Treatment

        9.5.2. By End-user 

        9.5.3. By Country

10. Europe Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Treatment, 2017–2028

        10.2.1. Radiation Therapy

        10.2.2. Chemotherapy

        10.2.3. Temozolomide

        10.2.4. Bevacizumab

        10.2.5. Carmustine

        10.2.6. Other Types of Chemotherapy                  

        10.2.7. Other Treatments

    10.3. Market Value Forecast, by End-user, 2017–2028

        10.3.1. Hospitals

        10.3.2. Ambulatory Surgical Centers

        10.3.3. Clinics

    10.4. Market Value Forecast, by Country/Sub-region, 2017–2028

        10.4.1. Germany 

        10.4.2. U.K. 

        10.4.3. France 

        10.4.4. Italy 

        10.4.5. Spain 

        10.4.6. Rest of Europe 

    10.5. Market Attractiveness Analysis 

        10.5.1. By Treatment

        10.5.2. By End-user 

        10.5.3. By Country/Sub-region

11. Asia Pacific Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Treatment, 2017–2028

        11.2.1. Radiation Therapy

        11.2.2. Chemotherapy

            11.2.2.1. Temozolomide

            11.2.2.2. Bevacizumab

            11.2.2.3. Carmustine

            11.2.2.4. Other Types of Chemotherapy

        11.2.3. Other Treatments

    11.3. Market Value Forecast, by End-user, 2017–2028

        11.3.1. Hospitals

        11.3.2. Ambulatory Surgical Centers

        11.3.3. Clinics

    11.4. Market Value Forecast, by Country/Sub-region, 2017–2028

        11.4.1. China 

        11.4.2. Japan 

        11.4.3. India 

        11.4.4. Australia & New Zealand 

        11.4.5. Rest of Asia Pacific 

    11.5. Market Attractiveness Analysis 

        11.5.1. By Treatment

        11.5.2. By Drug Class

        11.5.3. By End-user 

        11.5.4. By Country/Sub-region

12. Latin America Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Treatment, 2017–2028

        12.2.1. Radiation Therapy

        12.2.2. Chemotherapy

            12.2.2.1. Temozolomide

            12.2.2.2. Bevacizumab

            12.2.2.3. Carmustine

            12.2.2.4. Other Types of Chemotherapy 

        12.2.3. Other Treatments

    12.3. Market Value Forecast, by End-user, 2017–2028

        12.3.1. Hospitals

        12.3.2. Ambulatory Surgical Centers

        12.3.3. Clinics

    12.4. Market Value Forecast, by Country/Sub-region, 2017–2028

        12.4.1. Brazil 

        12.4.2. Mexico 

        12.4.3. Rest of Latin America 

    12.5. Market Attractiveness Analysis 

        12.5.1. By Treatment

        12.5.2. By Drug Class

        12.5.3. By End-user 

        12.5.4. By Country/Sub-region

13. Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Treatment, 2017–2028

        13.2.1. Radiation Therapy

        13.2.2. Chemotherapy

            13.2.2.1. Temozolomide

            13.2.2.2. Bevacizumab

            13.2.2.3. Carmustine

            13.2.2.4. Other Types of Chemotherapy

        13.2.3. Other Treatments

    13.3. Market Value Forecast, by End-user, 2017–2028

        13.3.1. Hospitals

        13.3.2. Ambulatory Surgical Centers

        13.3.3. Clinics

    13.4. Market Value Forecast, by Country/Sub-region, 2017–2028

        13.4.1. GCC Countries 

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa 

    13.5. Market Attractiveness Analysis 

        13.5.1. By Treatment

        13.5.2. By Drug Class

        13.5.3. By End-user 

        13.5.4. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player - Competition Matrix (by tier and size of companies)

    14.2. Market Share Analysis, by Company, 2020

    14.3. Company Profiles

        14.3.1. Merck & Co., Inc.

            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.1.2. Financial Analysis

            14.3.1.3. Growth Strategies

            14.3.1.4. SWOT Analysis

        14.3.2. F. Hoffmann-La Roche Ltd.

            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.2.2. Financial Analysis

            14.3.2.3. Growth Strategies

            14.3.2.4. SWOT Analysis

        14.3.3. Pfizer Inc.

            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.3.2. Financial Analysis

            14.3.3.3. Growth Strategies

            14.3.3.4. SWOT Analysis

        14.3.4. Amgen, Inc. 

            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.4.2. Financial Analysis

            14.3.4.3. Growth Strategies

            14.3.4.4. SWOT Analysis

        14.3.5. Teva Pharmaceutical Industries Ltd.

            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.5.2. Financial Analysis

            14.3.5.3. Growth Strategies

            14.3.5.4. SWOT Analysis

        14.3.6. Sun Pharmaceutical Industries Ltd.

            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.6.2. Financial Analysis

            14.3.6.3. Growth Strategies

            14.3.6.4. SWOT Analysis 

        14.3.7. Arbor Pharmaceuticals, LLC

            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.7.2. Financial Analysis

            14.3.7.3. Growth Strategies

            14.3.7.4. SWOT Analysis

        14.3.8. Amneal Pharmaceuticals

            14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.8.2. Financial Analysis

            14.3.8.3. Growth Strategies

            14.3.8.4. SWOT Analysis

        14.3.9. Karyopharm Therapeutics, Inc.

            14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.9.2. Financial Analysis

            14.3.9.3. Growth Strategies

            14.3.9.4. SWOT Analysis

        14.3.10. Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)

            14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.10.2. Financial Analysis

            14.3.10.3. Growth Strategies

            14.3.10.4. SWOT Analysis

List of Tables

TABLE 1: Market Snapshot: Global Glioblastoma Multiforme Treatment (GBM) Market

TABLE 2: Global Prevalence of Glioblastoma Multiforme worldwide

TABLE 3: Global Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Treatment, 2017–2031

TABLE 4: Global Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by End-user, 2017–2031

TABLE 5: Global Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Geography, 2017–2031

TABLE 6: North America Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Country, 2017–2031 

TABLE 7: North America Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Treatment, 2017–2031

TABLE 8: North America Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by End-user, 2017–2031 

TABLE 9: Europe Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Country/Sub-region, 2017–2031

TABLE 10: Europe Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Treatment, 2017–2031

TABLE 11: Europe Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by End-user, 2017–2031

TABLE 12: Asia Pacific Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Country/Sub-region, 2017–2031 

TABLE 13: Asia Pacific Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Treatment, 2017–2031

TABLE 14: Asia Pacific Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by End-user, 2017–2031 

TABLE 15: Latin America Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Country/Sub-region, 2017–2031

TABLE 16: Latin America Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Treatment, 2017–2031

TABLE 17: Latin America Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by End-user, 2017–2031

TABLE 18: Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Country/Sub-region, 2017–2031 

TABLE 19: Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by Treatment, 2017–2031

TABLE 20: Middle East & Africa Glioblastoma Multiforme Treatment (GBM) Market Revenue (US$ Mn), by End-user, 2017–2031

List of Figures

FIG. 1: Comparative Analysis: Global 3D Printing Market, by Treatment, 2021 & 2028 (%)

FIG. 2: Global Glioblastoma Multiforme Treatment (GBM) Market Segmentation

FIG. 3: Global Glioblastoma Multiforme Treatment (GBM) Market, by Drug Class, 2020

FIG. 4: Global Glioblastoma Multiforme Treatment (GBM) Market, by Treatment, 2020

FIG. 5: Global Glioblastoma Multiforme Treatment (GBM) Market: Drivers and Restraints

FIG. 6: Porter’s Five Forces Analysis for Glioblastoma Multiforme Treatment (GBM) Market

FIG. 7: Market Attractiveness Analysis: Glioblastoma Multiforme Treatment (GBM) Market, by Region

FIG. 8: Global Glioblastoma Multiforme Treatment (GBM) Market Share Analysis of Key Players

FIG. 9: Global Glioblastoma Multiforme Treatment (GBM) Market Segmentation, by Drug Class

FIG. 10: Global Tumor Treating Field (TTF) Therapy Market Value (US$ Mn), 2021–2028

FIG. 11: Global Radiation Therapy Market Value (US$ Mn), 2021–2028

FIG. 12: Global Targeted Therapy Market Value (US$ Mn), 2021–2028

FIG. 13: Global Temozolomide Market Value (US$ Mn), 2021–2028

FIG. 14: Global Bevacizumab Market Value (US$ Mn), 2021–2028

FIG. 15: Global Lomustine Market Value (US$ Mn), 2021–2028

FIG. 16: Global Targeted Therapy Market Value (US$ Mn), 2021–2028

FIG. 17: Global Tumor Treating Field (TTF) Therapy Market, 2021–2028

FIG. 18: Market Segmentation of Glioblastoma Multiforme Treatment (GBM) Market, by Drug Class

FIG. 19: North America Tumor Treating Field (TTF) Therapy Market Value (US$ Mn), 2021–2028

FIG. 20: North America Radiation Therapy Market Value (US$ Mn), 2021–2028

FIG. 21: North America Targeted Therapy Market Value (US$ Mn), 2021–2028

FIG. 22: North America Temozolomide Market Value (US$ Mn), 2021–2028

FIG. 23: North America Bevacizumab Market Value (US$ Mn), 2021–2028

FIG. 24: North America Lomustine Market Value (US$ Mn), 2021–2028

FIG. 25: North America Targeted Therapy Market Value (US$ Mn), 2021–2028

FIG. 26: North America Tumor Treating Field (TTF) Therapy Market, 2021–2028

FIG. 27: Europe Tumor Treating Field (TTF) Therapy Market Value (US$ Mn), 2021–2028

FIG. 28: Europe Radiation Therapy Market Value (US$ Mn), 2021–2028

FIG. 29: Europe Targeted Therapy Market Value (US$ Mn), 2021–2028

FIG. 30: Europe Temozolomide Market Value (US$ Mn), 2021–2028

FIG. 31: Europe Bevacizumab Market Value (US$ Mn), 2021–2028

FIG. 32: Europe Lomustine Market Value (US$ Mn), 2021–2028

FIG. 33: Europe Targeted Therapy Market Value (US$ Mn), 2021–2028

FIG. 34: Europe Tumor Treating Field (TTF) Therapy Market, 2021–2028

FIG. 35: Asia Pacific Tumor Treating Field (TTF) Therapy Market Value (US$ Mn), 2021–2028

FIG. 36: Asia Pacific Radiation Therapy Market Value (US$ Mn), 2021–2028

FIG. 37: Asia Pacific Targeted Therapy Market Value (US$ Mn), 2021–2028

FIG. 38: Asia Pacific Temozolomide Market Value (US$ Mn), 2021–2028

FIG. 39: Asia Pacific Bevacizumab Market Value (US$ Mn), 2021–2028

FIG. 40: Asia Pacific l Lomustine Market Value (US$ Mn), 2021–2028

FIG. 41: Asia Pacific Targeted Therapy Market Value (US$ Mn), 2021–2028

FIG. 42: Asia Pacific Tumor Treating Field (TTF) Therapy Market, 2021–2028

FIG. 43: Latin America Tumor Treating Field (TTF) Therapy Market Value (US$ Mn), 2021–2028

FIG. 44: Latin America Radiation Therapy Market Value (US$ Mn), 2021–2028

FIG. 45: Latin America Targeted Therapy Market Value (US$ Mn), 2021–2028

FIG. 46: Latin America Temozolomide Market Value (US$ Mn), 2021–2028

FIG. 47: Latin America Bevacizumab Market Value (US$ Mn), 2021–2028

FIG. 48: Latin America Lomustine Market Value (US$ Mn), 2021–2028

FIG. 49: Latin America Targeted Therapy Market Value (US$ Mn), 2021–2028

FIG. 50: Latin America Tumor Treating Field (TTF) Therapy Market, 2021–2028

FIG. 51: Middle East & Africa Tumor Treating Field (TTF) Therapy Market Value (US$ Mn), 2021–2028

FIG. 52: Middle East & Africa Radiation Therapy Market Value (US$ Mn), 2021–2028

FIG. 53: Middle East & Africa Targeted Therapy Market Value (US$ Mn), 2021–2028

FIG. 54: Middle East & Africa Temozolomide Market Value (US$ Mn), 2021–2028

FIG. 55: Middle East & Africa Bevacizumab Market Value (US$ Mn), 2021–2028

FIG. 56: Middle East & Africa Lomustine Market Value (US$ Mn), 2021–2028

FIG. 57: Middle East & Africa Targeted Therapy Market Value (US$ Mn), 2021–2028

FIG. 58: Middle East & Africa Tumor Treating Field (TTF) Therapy Market, 2021–2028

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Glioblastoma Multiforme Treatment (GBM) Market